Literature DB >> 35192689

Nrf2 Regulates β-Cell Mass by Suppressing β-Cell Death and Promoting β-Cell Proliferation.

Sharon Baumel-Alterzon1,2, Liora S Katz1, Gabriel Brill1, Clairete Jean-Pierre1, Yansui Li1, Isabelle Tse1, Shyam Biswal3, Adolfo Garcia-Ocaña1,2, Donald K Scott1,2.   

Abstract

Finding therapies that can protect and expand functional β-cell mass is a major goal of diabetes research. Here, we generated β-cell-specific conditional knockout and gain-of-function mouse models and used human islet transplant experiments to examine how manipulating Nrf2 levels affects β-cell survival, proliferation, and mass. Depletion of Nrf2 in β-cells results in decreased glucose-stimulated β-cell proliferation ex vivo and decreased adaptive β-cell proliferation and β-cell mass expansion after a high-fat diet in vivo. Nrf2 protects β-cells from apoptosis after a high-fat diet. Nrf2 loss of function decreases Pdx1 abundance and insulin content. Activating Nrf2 in a β-cell-specific manner increases β-cell proliferation and mass and improves glucose tolerance. Human islets transplanted under the kidney capsule of immunocompromised mice and treated systemically with bardoxolone methyl, an Nrf2 activator, display increased β-cell proliferation. Thus, by managing reactive oxygen species levels, Nrf2 regulates β-cell mass and is an exciting therapeutic target for expanding and protecting β-cell mass in diabetes.
© 2022 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35192689      PMCID: PMC9044139          DOI: 10.2337/db21-0581

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.337


  56 in total

1.  Pharmacological activation of Nrf2 pathway improves pancreatic islet isolation and transplantation.

Authors:  Shiri Li; Nosratola D Vaziri; Yuichi Masuda; Mohammad Hajighasemi-Ossareh; Lourdes Robles; Aimee Le; Kelly Vo; Jefferson Y Chan; Clarence E Foster; Michael J Stamos; Hirohito Ichii
Journal:  Cell Transplant       Date:  2015-01-09       Impact factor: 4.064

Review 2.  Sweet Sixteenth for ChREBP: Established Roles and Future Goals.

Authors:  Aya Abdul-Wahed; Sandra Guilmeau; Catherine Postic
Journal:  Cell Metab       Date:  2017-08-01       Impact factor: 27.287

3.  The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1.

Authors:  Masaaki Komatsu; Hirofumi Kurokawa; Satoshi Waguri; Keiko Taguchi; Akira Kobayashi; Yoshinobu Ichimura; Yu-Shin Sou; Izumi Ueno; Ayako Sakamoto; Kit I Tong; Mihee Kim; Yasumasa Nishito; Shun-ichiro Iemura; Tohru Natsume; Takashi Ueno; Eiki Kominami; Hozumi Motohashi; Keiji Tanaka; Masayuki Yamamoto
Journal:  Nat Cell Biol       Date:  2010-02-21       Impact factor: 28.824

4.  Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming.

Authors:  Yoichiro Mitsuishi; Keiko Taguchi; Yukie Kawatani; Tatsuhiro Shibata; Toshihiro Nukiwa; Hiroyuki Aburatani; Masayuki Yamamoto; Hozumi Motohashi
Journal:  Cancer Cell       Date:  2012-07-10       Impact factor: 31.743

5.  Targeted inactivation of hepatocyte growth factor receptor c-met in beta-cells leads to defective insulin secretion and GLUT-2 downregulation without alteration of beta-cell mass.

Authors:  Jennifer Roccisana; Vasumathi Reddy; Rupangi C Vasavada; Jose A Gonzalez-Pertusa; Mark A Magnuson; Adolfo Garcia-Ocaña
Journal:  Diabetes       Date:  2005-07       Impact factor: 9.461

6.  RPB5-Mediating Protein Promotes Cholangiocarcinoma Tumorigenesis and Drug Resistance by Competing With NRF2 for KEAP1 Binding.

Authors:  Zheng-Hua Wan; Tian-Yi Jiang; Yuan-Yuan Shi; Yu-Fei Pan; Yun-Kai Lin; Yun-Han Ma; Chun Yang; Xiao-Fan Feng; Li-Feng Huang; Xiao-Ni Kong; Zhi-Wen Ding; Ye-Xiong Tan; Li-Wei Dong; Hong-Yang Wang
Journal:  Hepatology       Date:  2020-02-20       Impact factor: 17.425

7.  Conditional gene targeting in mouse pancreatic ß-Cells: analysis of ectopic Cre transgene expression in the brain.

Authors:  Barton Wicksteed; Marcela Brissova; Wenbo Yan; Darren M Opland; Jennifer L Plank; Rachel B Reinert; Lorna M Dickson; Natalia A Tamarina; Louis H Philipson; Alena Shostak; Ernesto Bernal-Mizrachi; Lynda Elghazi; Michael W Roe; Patricia A Labosky; Martin G Myers; Maureen Gannon; Alvin C Powers; Peter J Dempsey
Journal:  Diabetes       Date:  2010-08-29       Impact factor: 9.461

Review 8.  Nrf2: The Master and Captain of Beta Cell Fate.

Authors:  Sharon Baumel-Alterzon; Liora S Katz; Gabriel Brill; Adolfo Garcia-Ocaña; Donald K Scott
Journal:  Trends Endocrinol Metab       Date:  2020-11-23       Impact factor: 12.015

9.  Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO.

Authors:  Anne Cleasby; Jeff Yon; Philip J Day; Caroline Richardson; Ian J Tickle; Pamela A Williams; James F Callahan; Robin Carr; Nestor Concha; Jeffrey K Kerns; Hongwei Qi; Thomas Sweitzer; Paris Ward; Thomas G Davies
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

Review 10.  Molecular Mechanisms Linking Oxidative Stress and Diabetes Mellitus.

Authors:  Habib Yaribeygi; Thozhukat Sathyapalan; Stephen L Atkin; Amirhossein Sahebkar
Journal:  Oxid Med Cell Longev       Date:  2020-03-09       Impact factor: 6.543

View more
  3 in total

1.  Lactiplantibacillus plantarum 299v supplementation modulates β-cell ER stress and antioxidative defense pathways and prevents type 1 diabetes in gluten-free BioBreeding rats.

Authors:  Pinar Sargin; Mark F Roethle; Shuang Jia; Tarun Pant; Ashley E Ciecko; Samantha N Atkinson; Nita H Salzman; Ru-Jeng Teng; Yi-Guang Chen; Susanne M Cabrera; Martin J Hessner
Journal:  Gut Microbes       Date:  2022 Jan-Dec

2.  Deletion of Thioredoxin Reductase Disrupts Redox Homeostasis and Impairs β-Cell Function.

Authors:  Jennifer S Stancill; Polly A Hansen; Angela J Mathison; Edward E Schmidt; John A Corbett
Journal:  Function (Oxf)       Date:  2022-07-04

Review 3.  Regulation of Pdx1 by oxidative stress and Nrf2 in pancreatic beta-cells.

Authors:  Sharon Baumel-Alterzon; Donald K Scott
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-15       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.